LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

K2B Therapeutics

K2B Therapeutics is a translational biotech company committed to helping cancer patients using the Protein RNA conjugates (PRC) modality that delivers siRNA specifically to the targeted cancer cells. We are expanding the PRC pipeline rapidly to bring these PRCs to the clinical phase.   

K2B Therapeutics logo
Website - Coming Soon
  • HoWon Kim CSO/Co-founder
  • Hyeyoun Chang Senior Scientist
  • Linda Freeburger Senior Research Associate